Mode
Text Size
Log in / Sign up
N/A N=120 Treatment

CorPath® GRX Neuro Study

Intracranial Aneurysm · Subarachnoid Hemorrhage · Headache

Enrolled (actual)
120
Serious AEs
34.2%
Results posted
Mar 2025
Primary outcome: Primary: Number of Participants With Procedural Technical Success. — 110 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Robotic Endovascular Procedure (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Corindus Inc.
Primary completion
Apr 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Procedural Technical Success.
110
PRIMARY
Number of Intra- and Peri-procedural Events.
4
SECONDARY
Robotically Navigate Device to the Target Aneurysm
SECONDARY
Robotically Deploy Therapeutic Device Into the Target Aneurysm
SECONDARY
Overall Procedure Time
117.3
SECONDARY
Fluoroscopy Time
51.9
SECONDARY
Patient Radiation Exposure
6886135.5
SECONDARY
Contrast Fluid Volume
185.4
SECONDARY
Adverse Events
SECONDARY
Number of Thromboembolic Events
17
SECONDARY
Devices Used Robotically
SECONDARY
Number of Participants With Aneurysm Occlusion
71; 5; 28; 6
SECONDARY
Number of Participants With Aneurysm Occlusion
71; 5; 28; 6

Summary

The primary objective of this study is to evaluate the effectiveness and safety of robotic-assisted endovascular embolization procedures compared to objective performance criteria for traditional, manual operation based on the scientific literature.

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years.
  • At least one cerebral aneurysm (unruptured) with indication for endovascular treatment; dome to neck ratio >1.5 or aneurysm neck width >4.0 mm.
  • The Investigator deems the procedure appropriate for both manual or robotic-assisted endovascular treatment.
  • The conscious subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Exclusion Criteria

  • Failure / unwillingness of the subject to provide informed consent, unless the EC has waived informed consent.
  • The Investigator determines that the subject or the neurovascular anatomy is not suitable for robotic-assisted endovascular treatment.
  • Women who are pregnant.
  • Persons under guardianship or curatorship.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04236856). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search